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Executive Summary  
Hypertensive disorders of pregnancy (HDPs)—which are major contributors of maternal and newborn 
mortality, morbidity, and disability—are preventable. About 24 percent of maternal deaths in Bangladesh 
each year are due to pre-eclampsia and eclampsia (PE/E). A known cause of death in women with PE/E is 
cerebrovascular accident (CVA), which occurs due to rapidly increasing blood pressure (BP). Elevated BP 
associated with pregnancy should be detected and appropriately managed before onset of convulsions 
(eclampsia) and other life-threatening complications. For women presenting with severe PE/E, magnesium 
sulphate (MgSO4) is the recommended drug for convulsion management. Anti-hypertensive medicines are 
also recommended for control of high BP, but the authorization to prescribe anti-hypertensive drugs, both 
for preventing and managing PE/E, is limited within lower level primary health care (PHC) facilities in 
Bangladesh. This study assessed the feasibility of PHC providers’ identification of HDP and prescription of 
alpha methyldopa (500mg single dose), prior to their referrals of patients to a higher level facility for MgSO4 
administration, if needed.   
This 15 month quasi-experimental study was part of the larger Ending Eclampsia project, to scale up a PHC 
model for early detection, prevention, and management of PE/E using a loading dose of MgSO4. The pre-
post study design featured both qualitative and quantitative data collection methods at baseline (2017) 
and endline (2018), in four sub-districts of Cumilla and Tangail districts, with two sub-districts (31 facilities) 
included in the intervention and the other two serving as comparison sub-districts (23 facilities). 
The intervention trained service providers on HDP and classification of hypertension, use and prescription 
of anti-hypertensive drugs (alpha methyldopa), and immediate referrals for patients to higher level facilities. 
Comparison facilities received training on HDP and referrals only—but did not receive training on 
prescription and use of anti-hypertensive drugs. Providers in the intervention facilities received a two day 
competency-based training followed up with a one day refresher training, while providers in comparison 
facilities received one day of training only. The World Health Organization (WHO) protocol for hypertension 
and anti-hypertensive drugs were used in the training.  
Almost all PHC providers from both groups, the intervention and comparison, at baseline and endline knew 
the correct definition of hypertension (≥140/90mmHg during pregnancy), and the correct drugs for BP 
control during pregnancy. Similarly, at endline almost all PHC providers knew types of hypertension during 
pregnancy, and classified mild, moderate, and severe hypertension correctly. Facility data show that a high 
proportion of women in both comparison and intervention facilities had their BP measured during the three 
month baseline period and the 15 month intervention period. There was significant improvement in 
knowledge of when to initiate anti-hypertensive drugs at endline among PHC providers in the intervention 
group (65%), compared to the comparison group (20%) (p<0.001). PHC provider knowledge of specific drug 
use (alpha methyldopa) to control BP during pregnancy also significantly improved at endline in the 
intervention group. Although not significant, about one third of providers in the intervention group 
prescribed alpha methyldopa at endline, compared to one sixth in the comparison group. 
Significant positive changes from baseline to endline were also observed for history-taking for hypertension 
or high BP (p<0.05) and albumin in urine tests (p<0.001) among intervention providers. In intervention 
facilities, 10 percent more women had their urine tested for albumin during the intervention period than 
during the baseline period. 
All women with moderate to severe hypertension at intervention facilities who required anti-hypertensives 
received alpha methyldopa—compared to no such women receiving it in the comparison group (p<0.001). 
Moreover, 45 percent of women with severe PE in the intervention group received a loading dose of MgSO4 




Almost all women (97%) with moderate to severe hypertension in all facilities were referred to higher level 
facilities for further management, with 62 percent of women from intervention facilities, and 51 percent 
from comparison facilities, actually completing the referral process at another facility. 
Study researchers followed all women from both groups, throughout their pregnancies, to assess their 
pregnancy outcomes. There were no significant differences between the two groups in gestational age at 
delivery, mode or place of delivery, assistance during delivery, or maternal outcomes. No maternal deaths 
occurred in either group over the 15 month intervention period, among those who sought services from 
these facilities.  
There were significant differences in newborn outcomes—live, stillborn, or ill—between the two groups 
(p=0.001). Significantly more infants died in the comparison group (14%, n=9) than in the intervention 
group (3%, n=3). Among women with HDPs, about four fifths delivered at 36 weeks or later in both groups, 
while a small proportion in both groups delivered before 33 weeks. Further analysis shows that 
hypertensive pregnant women who took alpha methyldopa were 1.36 times more likely to deliver a live 
infant than those who did not (AOR: 1.36, 95% CI:0.30-5.43). 
PHC providers demonstrated the ability to apply their knowledge correctly in hypertension detection and 
classification, as well as referring patients when appropriate. Policy-makers, program managers, service 
providers, and other stakeholders strongly suggest allowing PHC providers to prescribe anti-hypertensive 
drugs during pregnancy, and recommend scale up of this intervention in other parts of the country to 
achieve SDGs. The following recommendations emerged from this study: 
• PHC providers (FWVs, SACMOs, nurses) are capable of correctly measuring and classifying blood 
pressure and prescribing a single dose of alpha methyldopa prior to patient referrals to higher 
level facilities. This practice should be promoted.  
• PHC providers can be trained within three days on hypertension, PE/E, MgSO4, and anti-
hypertensive drugs, followed by a one day refresher workshop after three months.  
• Many women are not completing their referral courses, and further research is recommended to 
identify why women do not complete the referral process, and to understand these barriers and how 
to support women’s fulfillment of necessary higher level care.   
• To build on this study, which looked at a single dose of alpha methyldopa and referral, a pregnancy 
life course study with anti-hypertensive drugs prescribed by PHC providers is recommended, to 
assess their abilities to identify drug non-responsiveness, emerging danger signs and symptoms, 
appropriate times for hospitalization or physician intervention, as well assessing whether task sharing 
is correctly and adequately implemented. 
• The task sharing efforts with anti-hypertensive drugs, particularly alpha methyldopa, demonstrated 
within Ending Eclampsia’s PHC PE/E intervention, are recommended for other parts of the country, 







Introduction and Background  
Globally, about 10 percent of women experience a hypertensive disorder in pregnancy (HDP), a major 
contributor to maternal and newborn mortality, morbidity, and disability (Duley et al 2009, Steegers et al 
2010, Khan et al 2006). HDPs are classified into four categories, as recommended by the National High 
Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: 1) chronic 
hypertension, 2) pre-eclampsia/eclampsia (PE/E), 3) pre-eclampsia (PE) superimposed on chronic 
hypertension, and 4) gestational hypertension (Mammaro et al 2009).  
Pre-eclampsia, which is high blood pressure (BP) with significant proteinuria after 20 weeks of pregnancy 
gestation, complicates four to five percent of pregnancies (Steegers et al 2010, Abalos et al 2013, 
Arulkumaran et al 2013). Women in low- and middle income countries (LMICs) are seven times more likely 
to develop PE than those in higher income countries (WHO 2007). About 10 percent of PE patients develop 
severe PE/E (WHO 2011). Worldwide, about 14 percent of maternal deaths are due to HDPs (Say et al 
2014, WHO 2005, WHO 2007). Timely and effective care can prevent these deaths (Duley et al 2006). 
Factors preventing women from seeking or receiving care include poverty, distances to facilities, lack of 
relevant information, inadequate services, and cultural practices. Poor women in remote areas are least 
likely to receive adequate health care, especially in regions with low numbers of skilled health providers, 
such as sub-Saharan Africa and South Asia (PE Foundation 2016). 
Some women entering pregnancy may have pre-existing risk factors for HDP development, such as diseases 
like diabetes, chronic hypertension, chronic kidney disease, or autoimmune disease, or experienced HDP 
during a previous pregnancy, in addition to obesity, primiparity, age below 20 or older than 35, or a family 
history of HDP (Meads et al 2008, Action on Preeclampsia 2004). Women who have had gestational 
hypertension or PE are also associated with increased risk of developing high BP and complications later 
in life. Women with a history of PE but no proteinuria or hypertension at postnatal review (6 to 8 weeks 
after birth) have increased relative risk of kidney disease. Women with gestational hypertension have a risk 
of developing gestational hypertension in a future pregnancy ranging from about 16 percent to 47 percent, 
and their risk of developing PE in a future pregnancy ranges from two percent to seven percent.  
Among women with PE, their risk of gestational hypertension in a future pregnancy ranges from about 13 
percent to 53 percent, and their risk of developing PE again is 16 percent. The risk of developing PE in a 
future pregnancy increases to 25 percent if PE was complicated by severe PE, HELLP syndrome (a life-
threatening pregnancy complication characterized by hemolysis, elevated liver enzymes and low platelet 
count) or eclampsia, or pre-term birth before 34 weeks, and rises to 55 percent if prior PE led to birth before 
28 weeks. Women who have had PE have no additional risk of recurrence with an inter-pregnancy interval 
up to 10 years (RCOG 2011). 
In Bangladesh, HDPs, particularly PE/E, account for 24 percent of pregnant women’s deaths (BMMS 2017). 
A known cause of death in women with PE/E is cerebrovascular accident (CVA), due to rapidly increasing 
BP. Addressing HDP (especially PE/E) in a timely and effective manner reduces maternal morbidity and 
mortality. PE should be detected and appropriately managed prior to convulsions (i.e. eclampsia) and other 
life-threatening complications. 
Although many countries have approved MgSO4 for use at all levels of their health care systems, barriers 
persist. Lower level facilities’ access to anti-hypertensive drugs and low dose aspirin, for both PE/E 
management and prevention, is limited. Anti-hypertensives—including labetalol, alpha methyldopa, 
nifedipine, and hydralazine—are recommended by WHO for control of high BP but are not routine, except 




and are thereby not empowered to treat women presenting with HDPs. PHC providers in Bangladesh 
apparently do prescribe anti-hypertensives to pregnant women, even without official sanction, although 
sometimes with incorrect drugs (Warren et al 2015). 
WHO proposes task shifting where the health workforce is insufficient to provide adequate coverage with 
quality care (WHO 2008, 2012). The global recommendations and guidelines on task shifting propose the 
adoption or expansion of a task shifting approach as one method of strengthening and expanding the health 
workforce to rapidly increase access to health services. Reorganization and de-centralization of health 
services according to a task shifting approach can help to address the current shortages of health workers 
(ibid). Specific reorganization and decentralization recommended by WHO is rooted in the understanding 
that lower level cadres such as auxiliary nurses and midwives can administer anti-hypertensives for severe 
hypertension in pregnancy in the context where there is targeted monitoring and evaluation (WHO 2012). 
Nothing is known about Family Welfare Visitors’ (FWVs) and SACMOs’, the main actors in PHC facilities in 
Bangladesh, capability and suitability to provide anti-hypertensive services at PHC level. FWVs and SACMOs 
are a lower level service provider cadre similar to auxiliary nurses and midwives, with 18 months and 36 
months training, respectively. It is plausible that this group of providers can also be equipped with the 
appropriate and adequate knowledge, skills, and training for the management of moderate to severe 
hypertension in pregnancy and then refer these women to higher levels for further management. 
It is important to provide appropriate anti-hypertensives to women for moderate to severe hypertension in 
pregnancy at the first contact point with the health system to reduce negative outcomes due to delays in 
reaching a physician or facility. In Bangladesh, PHC providers are allowed to provide the loading dose of 
MgSO4 to initiate management of prior to referral. Therefore, FWVs, SACMOs, and nurses should also be 
equipped with the appropriate knowledge, and skills, in the management of moderate and severe 
hypertension using the recommended anti-hypertensives and then refer women to higher levels.   
The overall aim of this study was to assess the feasibility of PHC providers (FWVs, SACMOs, nurses), to 
detect HDPs in women, to prescribe alpha methyldopa (single dose) before referral to another facility and 
if needed, administer MgSO4.The findings of the study will help policy-makers decide if it feasible and 
acceptable for PHC providers to prescribe anti-hypertensive drugs during pregnancy. 
Specific Aims        
• To assess the feasibility of lower level service providers (FWVs, SACMOs, nurses) to identify and 
classify high BP among pregnant women during ANC visits;   
• To assess the ability of lower level service providers (FWVs, SACMOs, nurses) to prescribe the anti-
hypertensive drug—alpha methyldopa (single dose)— appropriately to pregnant women with moderate 
to severe hypertension including PE/E before referral (this includes prescribing/administering MgSO4 
for severe PE/E prior to referral); 
• To refer identified patients to secondary facilities/physicians with anti-hypertensive drugs for further 
assessment and management. 
Hypothesis 
• Lower level service providers will be able to identify hypertensive disorders among pregnant women 






Primary Health Care Provider: Family Welfare Visitors (FWVs), Sub Assistant Community Medical Officers 
(SACMOs), Nurses, and Midwives who sit at: Union Health and Family Welfare Centre (UHFWC) and Upazila 
Health Complex (UHC), District Hospital (DH) or Mother and Child Welfare Centre (MCWC) 
High blood pressure (BP) during pregnancy: BP of pregnant women of 140/90 mmHg or more for two 
consecutive measurements, four hours apart, otherwise normal BP 
Mild hypertension: BP of pregnant women of 140 to 149/90 to 99 mmHg or more for two consecutive 
measurements, four hours apart 
Moderate hypertension: BP of pregnant women of 150 to 159/100 to 109 mmHg for two consecutive 
measurements, four hours apart 
Severe hypertension: BP of pregnant women of 160/110 mmHg or more for two consecutive 
measurements, four hours apart 
Chronic hypertension: BP >140/90 before pregnancy, after 20 weeks, or during pregnancy and not 
resolving postpartum 
Gestational hypertension: BP of pregnant women after 20 weeks of pregnancy, during delivery or 48 hours 
after delivery is 140/90 mmHg or more for two consecutive measurements, four hours apart 
Pre-Eclampsia: High BP (140/90 mmHg or higher) and excess protein in the urine (albuminuria, presence 
of an excess of albumin in the urine) determined by dipstick test after 20 weeks of pregnancy in a woman 
who previously had normal BP  
Severe pre-eclampsia: Severe pre-eclampsia is pre-eclampsia with severe hypertension and/or with 
symptoms, and/or biochemical and/or hematological impairment (NICE 2010); diastolic BP ≥110 mmHg 
or systolic ≥160mmHg after two measurements, four hours apart with albumin in urine; and/or with severe 
headache, and/or blurred vision, and/or pain in upper abdomen 
HELLP syndrome: Life-threatening pregnancy complication characterized by hemolysis, elevated liver 
enzymes, and a low platelet count 
Eclampsia: High BP (140/90 mmHg or greater), excess protein in urine (albuminuria/proteinuria), and 
generalized convulsions or seizures during pregnancy, labor or within 42 days of delivery in the absence of 
epilepsy or another condition predisposing to convulsions (Sibai 2005); eclampsia occurs 38 percent to 55 
percent of the time during pregnancy; 13 percent to 36 percent intrapartum; five percent to 39 percent 
within 48 hours of childbirth; and five to 17 percent more than 48 hours after birth   
Stroke: Hemiparesis and/or blindness developed during pregnancy or in the 42 days postpartum lasting 
greater than 48 hours 







Bangladesh has a uniform health and family planning (FP) infrastructure (Figure 1), with each district 
featuring a District Hospital (DH) that includes a Mother and Child Welfare Center (MCWC), each managed 
by the Director General for FP (DGFP). Every sub-district has an Upazila Health Complex (UHC) with a FP 
unit, and every union has a Union Health and Family Welfare Centre (UH&FWC) for FP along with 12 to 16 
Community Clinics (CCs) for health and FP services. Each district has eight to 10 sub-districts, and every 
sub-district has eight to 10 unions; unions each have three wards, and each ward has three or four CCs. 
District hospitals and MCWCs are considered secondary facilities, whereas UHCs, UH&FWCs, and CCs are 
considered PHC facilities. 
Figure 1. Health and FP Infrastructures in Bangladesh  
 
 
This study was part of a larger study of the Ending Eclampsia Project, a USAID-funded endeavor supporting 
the prevention, early detection, and management of PE/E at PHC facilities in four districts in Bangladesh. 
Ending Eclampsia’s primary study involved 136 facilities—including 116 UH&FWCs, 11 UHCs, five MCWCs, 
two DHs, and two medical colleges—in 12 sub-districts, and trained  PHC providers to detect (e.g. measure 
BP, test urine for albumin) and manage PE/E (administer loading dose of MgSO4), and ensured availability 
of commodities and supplies, along with referrals (Warren et al 2016). All PHC providers provide ANC and 
PNC services, except male SACMOs, who only provide them in the absence of FWVs and nurses.  
This focused study, introducing anti-hypertensive drugs at PHC facilities, was conducted in four sub-districts 
of Cumilla and Tangail districts, following consultations with DGFP. Two sub-districts were assigned to the 
intervention (29 facilities) and two were assigned to the comparison (21 facilities) including four referral 
facilities (UHCs) and were similar in health infrastructure, service providers, populations, fertility, and 
health-seeking behaviors. This study was implemented at UH&FWCs and UHCs, as well as in both districts’ 
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The study employed a quasi-experimental design with two sub-districts each assigned intervention and 
comparison sites. There was enough distance between the sub-districts to avoid any contamination. All PHC 
facilities in the four sub-districts were included in the study, in addition to district referral facilities.  
Data Collection  
Service statistics were collected for three months preceding the study, and then monthly throughout the 
15 months of the study.  
Service Provider and Program Manager Interviews 
PHC service providers’ knowledge, attitudes, and practices (KAP) were assessed in two ways. To assess 
their knowledge acquired through training by the project, pre- and post-training tests were conducted 
through self-administered questionnaires. Secondly, the research team administered a cross-sectional 
survey in all 54 PHC facilities including the four referral facilities, to assess service providers’ KAP at prior 
to the intervention and after the 15 month intervention period. Additional questions were added to the 
service providers’ questionnaire at the 15 month assessment to assess program impact. Ten program 
managers working in the four sub-districts and eight central policy-makers and other stakeholders were 
interviewed after 15 months as well for their opinions and experiences of PHC providers’ administration of 
anti-hypertensive drugs. The primary sampling unit was a health care facility, and service provider data 
were collected from trained, re-trained, and mentored providers after 15 months. It is possible that service 
providers, program managers, and policy-makers were not at the same facilities as during initial baseline 
due to transfers or new postings; however, newly posted providers were all trained for the intervention. 
Observations of Client and Provider Interactions  
Client and provider interactions (CPIs) were observed both before (n=99) and after (n=129) the intervention 
in all study sites, using a checklist. CPI observations focused on PHC provider practices with ANC clients, 
specifically for PE/E including BP measurement, history taking, urine testing, and client documentation. 
Upon explaining the study’s objectives and purposes, the research assistant obtained permission from each 
PHC provider as well as every client, for their observation of service provision and client documentation.   
Facility Readiness Assessments  
Facility readiness of the core PE/E intervention of Ending Eclampsia project was assessed three months 
before the anti-hypertensive study. Additionally, a post-intervention assessment was conducted after the 
15 month intervention period. The facility readiness assessment was conducted to determine the 
availability of commodities and equipment for effective managements of HDPs. The pre- and post-
intervention assessments were conducted in all comparison and intervention facilities. 
Collection of Service Statistics 
Three months of pre-intervention service statistics on hypertension and PE/E among ANC clients were 
collected from all study facilities. Subsequently, monthly service statistics for 15 months (May 2017 to July 
2018) were also collected on hypertension and PE/E at all facilities and compared with baseline pre-
intervention service statistics, from February to April 2017, to determine if the intervention had any impact 




Recruitment of Pregnant Women with High Blood Pressure 
Any ANC client with moderate to severe hypertension from both intervention and comparison facilities who 
were 15 years of age or older, had chronic or gestational increased BP, with any duration of pregnancy, and 
agreed to participate in the study and provided informed consent, was enrolled in the study by the service 
providers using an enrolment form. Although the age of consent in Bangladesh is 18 years, pregnant 
women younger than 18 are considered emancipated by virtue of their marital and pregnancy status. Upon 
explaining the study objectives and purposes, eligible clients consented to PHC providers to enroll in the 
study and providers invited eligible clients to participate to fill-up enrolment form in the study. Addresses, 
socio-demographic characteristics, and telephone numbers of those who agreed to participate were 
recorded on the enrolment form by service providers. Participants’ permission was also taken to conduct 
follow up interviews in their homes during postnatal period. Interviewers reminded each respondent they 
had agreed to a follow up interview by showing them the enrolment form. All respondents gave their consent 
to take part in this study. Interviewers informed respondents on the purpose of the follow up interview and 
obtain consent again before starting the interview.  Each enrolled client was followed-up until delivery and 
into the postnatal period to determine compliance with referral and pregnancy outcomes by DMOs.   
Enrolled Client In-Depth Interviews 
A sample of enrolled participants from both intervention and comparison facilities participated in in-depth 
interviews to explore their perceptions on quality of care received at the facility during the study as well as 
the referral process. The clients were interviewed at their homes.  
TABLE 1  Quantitative and qualitative data collection by intervention and comparison facilities 
 Type of data Baseline Endline Intervention  Comparison Total Intervention Comparison Total 
Quantitative data collection        
Service provider interview 49 52 101 47 50 97 
Interview with women with HDP - - - 89 63 152 
Client provider interaction 57 42 99 70 59 129 
Facility Inventory: commodities/supplies 31 23 54 31 23 54 
Qualitative data collection  
IDIs with Program Manager (sub-district) - 5 5 10 
IDIs with Policy-makers (central)  - - 8 
IDIs with HDP women - 13 7 20 
Monitoring service statistics  
(18 months) 
3 months 15 months 
Monthly service uptake collected from 54 facilities for 18 
months including 3 months pre-intervention data 
IDIs: in-depth interviews 
Intervention Implementation 
Service providers in the intervention facilities received training on three components: 1) on HDPs and 
classification of hypertension, 2) on one anti-hypertensive drug (alpha methyldopa), and 3) on when to refer 
to a higher facility. Providers were also trained in the two comparison sub-districts, but did not receive 






TABLE 2  Intervention design 
Intervention Intervention group 
Comparison 
group 
Training service providers (FWVs, SACMOs, nurses) on HDPs and HTN 
classification      
Training of service providers (FWVs, SACMOs, nurses) on alpha methyldopa 
(procured and made available in study facilities by the project)     - 
Referral to a higher level facility     
 
Providers at intervention facilities were provided a two day competency-based training followed by a one 
day refresher workshop three months after the initial training. Trainings were facilitated by master trainers 
from the Ending Eclampsia project selected from both local and central MoHFW units, along with experts 
from the Obstetrics and Gynecological Society of Bangladesh (OGSB) and Population Council staff. Pre- and 
post-training tests assessed immediate changes in provider knowledge. The training curriculum was based 
on World Health Organization (WHO) guidelines and Bangladesh’s national service delivery protocol for 
PE/E (WHO 2011, DGFP 2015). Hypertension diagnosis and treatment protocols (Appendix A) and a referral 
“decision tree” for HDPs (Appendix C), developed from Jhpiego Helping Mother Survives and WHO 
recommendations, were supplied to providers to guide their detection, management, and referral of women 
with HDPs.  
The hypertension diagnosis and treatment protocol and decision tree describe ways of identifying HDP 
during ANC and PNC visits, how to classify hypertension as chronic HTN, gestational hypertension or pre-
eclampsia, differences between HTN and PE/E, the definitions of mild, moderate and severe HTN and PE/E, 
and management of HTN and PE/E. The guidelines also provide information on grading hypertension as 
mild, moderate and severe, and management for each category.  
Provider training also included a skills-building session for correctly measuring BP, how to conduct an 
albumin test of urine with dipsticks, when to administer alpha methyldopa, and patient counseling and 
referral processes. Providers were also informed of why and how to correctly document essential ANC 
service elements, alpha methyldopa and MgSO4 provision, and referrals. Providers were also oriented on 
the study’s procedures, ethical issues, as well as participant enrollment processes and informed consent 
procedures.  
PHC providers were trained only to prescribe and dispense a single dose of alpha methyldopa since the 
National Technical Committee approved only a test of this drug.  
• For mild hypertension, providers in intervention facilities were trained to only monitor BP regularly.  
• For moderate hypertension, providers in intervention facilities were advised to prescribe a single 
500mg dose of alpha methyldopa and then refer to a facility or physician for further management.  
• For severe hypertension, providers in intervention facilities, in addition to prescribing a single 500mg 
dose of alpha methyldopa, administered a loading dose of MgSO4 and referred patients to referral 
facility for further management.  
Providers in comparison facilities participated in a one day training on identifying hypertensive pregnant 
women and referring patients to secondary facilities. They were not trained on alpha methyldopa. Job aids 
on managing hypertension with alpha methyldopa were not provided to comparison facility PHC providers.  
The refresher workshop for providers at intervention facilities was organized for one day, three months after 
their initial training, to review providers’ activities, share their experiences with patients, resolve any issues, 




In addition to these trainings, PHC providers at intervention facilities were mentored on detecting, 
classifying, and managing HDPs including hypertension (systolic BP [sBP] of ≥140mmHg and or diastolic 
BP [dBP] of ≥90mmHg measured on two different occasions, two hours apart), chronic hypertension 
(isolated hypertension diagnosed before the index pregnancy or detected before 20 weeks of gestation and 
continue after delivery), gestational hypertension (isolated hypertension diagnosed for the first time after 
20 weeks of index pregnancy without proteinuria), and PE (gestational hypertension and proteinuria of ≥++ 
using a urine dipstick).  
Supply of Alpha Methyldopa Anti-Hypertensive Drug  
Primary health care providers are not allowed to prescribe anti-hypertensive drugs, which are not supplied 
to PHC facilities by MoHFW. The Ending Eclampsia project, with MacArthur Foundation support, procured 
alpha methyldopa and distributed it to the study intervention facilities, with each PHC provider supplied a 
box of 30 alpha methyldopa 500mg tablets. Monitoring visits regularly checked drug supplies for 
replenishment.  
An initial 500mg alpha methyldopa tablet was given to every moderate to severe hypertensive pregnant 
woman, who were then referred to a physician or referral facility. 
Client Referrals 
Women were referred to a physician at a secondary or higher level facility, guided by a decision tree (job 
aid and treatment algorithm in Appendix A, figures 1 and 2). The BP of women suffering from mild 
hypertension was monitored in all facilities. If a woman at an intervention facility experienced moderate 
hypertension, she was given a single dose of alpha methyldopa (500mg) and then referred to a physician 
or referral facility for further management. In a comparison facility, if a woman suffered from moderate 
hypertension she was referred to a physician or referral facility for further management without any 
provision of alpha methyldopa.  
Women who experienced severe PE/E at both intervention and comparison facilities were administered a 
10mg loading dose of MgSO4 and referred to higher level facilities for further management, and women at 
intervention facilities were also given a single dose of alpha methyldopa. To track referrals at both 
intervention and comparison sites, each provider completed a referral slip, providing a duplicate to the 
client to present at the referral facility. If any referred client did not present at a referral facility, the service 
provider or District Monitoring Officer (DMO) called the client or her family to directly confirm whether she 
went to a tertiary facility, and if not, why. 
Monitoring Primary Health Care Provider Service Provision 
Service providers and their provision of services were monitored in two ways. PHC providers were monitored 
and mentored by a project-recruited DMO each month, when client records were reviewed and service 
statistics were collected to ensure PHC providers’ compliance with ethical and clinical standards. DMOs 
also attended PHC providers’ monthly sub-district meetings and cited any issues that needed to be 
discussed. DMOs also accompanied local supervisors when needed. In addition, a medical professional 
from the Council conducted quarterly monitoring and mentoring visits, sometimes with central program 
managers from DGFP and DGHS, to ensure PHC providers’ compliance with ethical and clinical standards.  
Monitoring visits observed PHC providers’ measurement and detection of BP, urine albumin, as well as 
adverse events, for documentation. When no incidences of hypertension had occurred at a facility, PHC 




Figure 2 Diagnosis of type and level of high BP during pregnancy and its management  
(algorithm for comparison and intervention facilities) 
Blood pressure Albumin in urine 
Sign/ 
Symptom* HTN Diagnosis 
Management 
in comparison facilities 
Management  









No • Mild HTN 
• PE • Refer • Refer 
Yes • Mild HTN 
• Severe PE 
• Injection MgSO4  
loading dose (10gm)** 
• Refer 




No No Mild HTN 
• Advice to rest 
• Return for follow up  
after 3 days  
• Refer 
• Advice to rest 
• Return for follow up 










No • Moderate HTN 
• PE • Refer 
• 1 tablet Alpha 
methyldopa (500mg)  
• Refer 
Yes • Moderate HTN 
• Severe PE 
• Injection MgSO4  
loading dose (10gm) 
• Refer 
• 1 tablet Alpha 
methyldopa (500mg)  
• Injection MgSO4 
loading dose (10gm) 
• Refer 
No No • Moderate HTN • Refer 












No • Severe HTN 
• Severe PE 
• Injection MgSO4  
loading dose (10gm) 
• Refer 
• 1 tablet Alpha 
methyldopa (500mg)  
• Injection MgSO4 
loading dose (10gm) 
• Refer 
Yes • Severe HTN 
• Severe PE 
• Injection MgSO4  
loading dose (10gm) 
• Refer 
• 1 tablet Alpha 
methyldopa (500mg)  
• Injection MgSO4 
loading dose (10gm) 
• Refer 
No No • Severe HTN 
• Severe PE 
• Injection MgSO4  
loading dose (10gm) 
• Refer 
• 1 tablet Alpha 
methyldopa (500mg)  
• Injection MgSO4 
loading dose (10gm) 
• Refer 
Any high BP 
level 
Yes Convulsion Eclampsia 
• Injection MgSO4  
loading dose (10gm) 
• Refer 
• 1 tablet Alpha 
methyldopa (500mg)  
• Injection MgSO4 
loading dose (10gm) 
• Refer 
No Convulsion Eclampsia 
• Injection MgSO4  
loading dose (10gm) 
• Refer 
• 1 tablet Alpha 
methyldopa (500mg)  
• Injection MgSO4 
loading dose (10gm) 
• Refer 
*sign/symptom: severe headache, blurred vision and upper abdominal pain; ** while Pritchard regime recommended 14gm MgSO4 




Data Management and Analysis 
A 10 member data collection team including two supervisors was recruited and trained for five days on the 
study’s objectives, survey tools, procedures, and ethical conduct of data collection. The researchers were 
also given practical training in the field on data collection for one day, out of range of the study area. One 
group of four data collectors and a supervisor was assembled for quantitative data collection, with another 
group of four interviewers and a supervisor for qualitative data collection.  
All completed questionnaires were checked by the supervisors in the field and sent to the Council office for 
further editing, entry, and analysis. Quantitative data were edited, coded, and analyzed using STATA/SAS 
software. Data entry employed CSPro, and double entries were performed to minimize data entry errors. 
Atlas.ti was used for qualitative data analysis. 
Descriptive, bivariate, and comparative analyses (Chi-Square test and Fisher’s Exact test) were performed, 
and their results are presented in this report as frequencies and percentages. To answer the research 
question “Are lower level service providers able to identify, classify and manage hypertensive disorders in 
pregnancy appropriately with alpha methyldopa?” analysis determined associations and causal effects of 
the intervention. A difference in difference analysis was conducted, with change effects and mean 
difference, and net intervention effects (NIE), calculated at 95 percent level of significance.  
Qualitative interviews were recorded in hand-written notes reinforced by audio recordings that were 
transcribed and translated into English. Thematic coding was prepared, and content and thematic analysis 
employed Atlas.ti. Findings were triangulated in thematic areas. 
Ethical Review and Informed Consent  
Ethical review and approval of this study protocol was obtained from both Population Council’s Institutional 
Review Board in New York (as Protocol 731) and the Bangladesh Medical Research Council’s (BMRC) Ethics 
Committee. Participation in this study was voluntary, and all participants were guided through the informed 







Service Providers’ Background Characteristics 
There were no significant differences in intervention and comparison facility providers’ background 
characteristics at baseline and endline (Table 3). About four fifths of PHC providers were female at endline 
at all facilities. Almost all PHC providers had received training on maternal health, FP, and child health 
within the preceding three years, at baseline and endline, in both intervention and comparison facilities. 
TABLE 3  Demographic characteristics of PHC providers in comparison and intervention facilities 
Characteristic 
Comparison, n (%) Intervention, n (%) 




Female 34 (65.4) 37 (74.0) 0.34 38 (77.6) 37 (78.7) 0.90 Male 18 (34.6) 13 (26.0) 11 (22.4) 10 (21.3) 
Age (years) 
<30  5 (9.6) 6 (12.0) 
0.62 
6 (12.2) 5 (10.6) 
0.74 30-39 9 (17.3) 9 (18.0) 8 (16.3) 12 (25.6) 40-49 15 (28.9) 19 (38.0) 13 (26.5) 11 (23.4) 
>=50  23 (44.2) 16 (32.0) 22 (44.9) 19 (40.4) 
Type of service providers 
Nurse/FWV 30 (57.7) 33 (66.0) 0.39 31 (63.3) 32 (68.1) 0.62 SACMO 22 (42.3) 17 (34.0) 18 (36.7) 15 (31.9) 
Years of work in PHC facility 
<6 22 (42.2) 19 (38.0) 
0.90 
18 (36.7) 19 (40.4) 
0.32 6-10  15 (28.9) 15 (30.0) 17 (34.7) 10 (21.3) 
>10 15 (28.9) 16 (32.0) 14 (28.6) 18 (38.3) 
Resident at facility 21 (40.4) 19 (38.0) 0.81 21 (42.9) 16 (34.0) 0.38 
Received any training  
on maternal health, FP,  
child health in last 3 years 
49 (94.3) 50 (100.0) 0.24b 47 (95.9) 47 (100.0) 0.50b 
(n) (52) (50)  (49) (47)  
a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test 
Pregnant Women with Hypertensive Disorders’ Background Characteristics  
While educational status and gestational age were similar in both groups of pregnant women, there were 
significantly more multipara women recruited in the intervention group than in the comparison group 
(p<0.05). There was no substantial difference in proteinuria detected in women in either facility group, 
however there was a marginally significant difference in past medical history between the two groups 
(p=0.05).   
TABLE 4  Socio-demographic characteristics of pregnant women at enrollment 
Characteristic Total, n (%) Comparison, n (%) Intervention, n (%) p valuea 
Age (Years)  
15-19  20 (13.2) 11 (17.5) 9 (10.1) 
0.57b 
20-24  44 (28.9) 18 (28.6) 26 (29.2) 
25-29 38 (25.0) 16 (25.4) 22 (24.7) 
30-34  27 (17.8) 12 (19.1) 15 (16.9) 
35-39  20 (13.2) 5 (7.9) 15 (16.9) 




Characteristic Total, n (%) Comparison, n (%) Intervention, n (%) p valuea 
Education  
No formal education 11 (7.2) 5 (7.9) 6 (6.7) 
0.14b 
Primary  70 (46.1) 35 (55.6) 35 (39.3) 
Secondary 53 (34.8) 18 (28.6) 35 (39.3) 
Higher Secondary 13 (8.6) 5 (7.9) 8 (8.9) 
Graduate level and above 5 (3.3) 0 (0.0) 5 (5.6) 
Gravida  
Primipara 61 (40.1) 33 (52.4) 28 (31.5) 0.04 Multipara 91 (59.9) 30 (47.6) 61 (68.5) 
Gestational age (weeks)  
<21 9 (5.9) 3 (4.8) 6 (6.7) 
0.11b 
21-25 18 (11.8) 3 (4.8) 15 (16.9) 
26-30 18 (11.8) 10 (15.9) 8 (8.9) 
31-35 30 (19.7) 11 (17.5) 19 (21.4) 
>35 77 (50.7) 36 (57.1) 41 (46.1) 
BP  
<160/110 mmHg 116 (76.3) 52 (82.5) 64 (71.9) 0.13 ≥160/110 mmHg 36 (23.7) 11 (17.5) 25 (28.1) 
Proteinuria  
+1 38 (25.0) 16 (25.4) 22 (24.7) 
0.47b +2 23 (15.1) 9 (14.3) 14 (15.7) +3 11 (7.2) 7 (11.1) 4 (4.5) 
Trace/Nil 80 (52.6) 31 (49.2) 49 (55.1) 
Have any past medical history?  
Yes 22 (14.5) 5 (7.9) 17 (19.1) 0.05 No 130 (85.5) 58 (92.1) 72 (80.9) 
(n) (152) (63) (89)  
Type of past medical history *  
Chronic HTN 9 (40.9) 1 (20.0) 8 (47.1) 0.76b 
Diabetes 6 (27.3) 1 (20.0) 5 (29.4) 0.68b 
Renal disease 1 (4.6) 0 (0.0) 1 (5.9) 0.58b 
Cardiovascular disease 1 (4.6) 0 (0.0) 1 (5.9) 0.58b 
Family history of HTN 3 (13.6) 2 (40.0) 1 (5.9) 0.12b 
PE/E 3 (13.6) 1 (20.0) 2 (11.8) 0.56b 
(n) (22) (5) (17)  
* Multiple response; a Pearson chi-square test, unless otherwise indicated; b Fisher’s exact test 
Pre- and Post-Training Tests of Primary Health Care Providers 
All PHC providers’ knowledge and perceptions of HDP, PE/E, and anti-hypertensive drugs were assessed 
before and after their basic trainings in a self-administered questionnaire. A total of 52 providers from 
comparison facilities and 50 from intervention facilities attended the trainings. Table 5 (following page) 
lists the pre- and post-training test results of PHC providers, indicating significant improvements in 
knowledge after the trainings.  
Although significant increases in knowledge were seen, knowledge gains were not observed among all 
providers, however, which indicates need for refresher training or continuous mentoring. For example, 21 
percent and 12 percent of providers in comparison and intervention facilities, respectively, did not correctly 





TABLE 5  Pre- and post-basic training tests results of providers  
Statement 




valuea n % n % n % n % 
a) Every woman’s BP would 
increase during pregnancy 
Yes 12 23.1 2 3.8 
<0.001 
11 22.0 3 6.0 
<0.001 No 38 73.1 50 96.2 38 76.0 47 94.0 
Dk 2 3.8 0 0.0 1 2.0 0 0.0 
b) Chronic hypertension is high BP 
above 140/90 mmHg among 
pregnant women in any time 
before and after pregnancy 
Yes 31 59.6 45 86.5 
<0.001 
32 64.0 48 96.0 
<0.001 
No 17 32.7 5 9.6 17 34.0 2 4.0 
Dk 4 7.7 2 3.8 1 2.0 0 0.0 
c) PE is a condition in pregnancy 
with high BP (>140/90 mmHg) 
after 20 weeks’ gestation 
Yes 33 63.5 11 21.2 
<0.001 
30 60.0 8 16.0 
0.052 No 13 25.0 41 78.8 18 36.0 42 84.0 
Dk 6 11.5 0 0.0 2 4.0 0 0.0 
d) PE is a condition in pregnancy 
with high BP (>140/90 mmHg) + 
urine albumin after 20 weeks’ 
gestation 
Yes 30 57.7 41 78.8 
<0.001 
20 40.0 44 88.0 
<0.001 
No 20 38.5 11 21.2 30 60.0 6 12.0 
Dk 2 3.8 0 0.0 0 0.0 0 0.0 
e) Calcium can be provided after 20 
weeks pregnancy for PE 
prevention  
Yes 21 40.4 26 50.0  14 28.0 5 10.0 
<0.001 No 24 46.2 24 46.2 33 66.0 45 90.0 
Dk 7 13.5 2 3.8 0.017 3 6.0 0 0.0 
f) Loading dose of MgS04 for  
prevention and treatment of 
convulsion in eclampsia is 10gm 
intramuscular injection 
Yes 33 63.5 50 96.2 
<0.001 
35 70.0 48 96.0 
<0.001 
No 7 13.5 1 1.9 14 28.0 2 4.0 
Dk 12 23.1 1 1.9 1 2.0 0 0.0 
g) Pregnant women should not use 
any anti-hypertensive drug to 
control BP during severe PE/E 
Yes 8 15.4 12 23.1 
<0.001 
14 28.0 8 16.0 
<0.001 No 36 69.2 40 76.9 35 70.0 42 84.0 
Dk 8 15.4 0 0.0 1 2.0 0 0.0 
h) If a pregnant woman comes in 
ANC visit at 30 weeks and her BP 
is 180/115 with albumin in 
urine, severe headache and 
blurred vision—suffering from 
chronic HTN 
Yes 31 59.6 21 40.4 
0.127 
25 50.0 5 10.0 
<0.001 
No 17 32.7 30 57.7 25 50.0 45 90.0 
Dk 4 7.7 1 1.9 0 0.0 0 0.0 
i) If a pregnant woman attends 
ANC at 12 weeks and BP is 160/ 
100 with no urine albumin—
suffering from PE  
Yes 26 50.0 21 40.4 
0.292 
28 56.0 8 16.0 
0.02 
No 23 44.2 30 57.7 19 38.0 42 84.0 
Dk 3 5.8 1 1.9 3 6.0 0 0.0 
j) If a pregnant woman attends 
ANC at 36 weeks and BP >140/ 
90 mmHg with albumin in urine, 
and then one week later her 
husband brings her with 
convulsion—suffering from 
eclampsia 
Yes 41 78.8 48 92.3 
<0.001 
29 58.0 43 86.0 
<0.001 
No 8 15.4 3 5.8 18 36.0 6 12.0 
Dk 3 5.8 1 1.9 3 6.0 1 2.0 
k) Alpha methyldopa can be used  
to control BP during pregnancy 
Yes 23 44.2 32 61.5 
<0.001 
8 16.0 30 60.0 
0.04 No 16 30.8 17 32.7 37 74.0 18 36.0 
Dk 13 25.0 3 5.8 5 10.0 2 4.0 






Effects of the Intervention  
Provider competence in managing hypertensive disorders of pregnancy 
Almost all PHC providers, in both groups, at baseline and endline knew the correct definition of hypertension 
(≥140/ 90mmHg during pregnancy). Similarly, almost all PHC providers who knew the types of HDP could 
grade or classify hypertension as mild, moderate, and severe at endline. There was significant knowledge 
improvement for when to initiate anti-hypertensive drugs, although not enough, among PHC providers in 
the intervention group (65%), compared to only 20 percent in the comparison group (p<0.001).  
While knowledge of when to administer anti-hypertensive drugs was not conveyed in the Ending Eclampsia 
project’s core intervention, findings show significant improvements. Other variables, such as definition of 
hypertension, types of HDP, and classification of hypertension, discussed in the project’s core intervention 
did not improve as much, as providers’ knowledge of them was already high.  
TABLE 6  Intervention effects on provider competencies in managing pregnancy hypertension  
Provider 
Competency 
Comparison, n (%) Intervention, n (%)    













(100.0) 2.0 -0.002 4.4 0.93 
Knew types of HDP 
















(95.7) 42.6 0.063 22.3 0.07 
PE 52  (100.0) 
50 




(100.0) 2.0 0.009 2.0 0.32 






(72.3) 29.4 -0.153 7.5 0.58 






(100.0) 2.0 -0.011 2.0 0.31 
Correctly classified hypertension (HTN) 
Mild HTN 45  (86.5) 
47 




(100.0) 9.2 0.046 -1.3 0.85 






(97.9) 18.3 -0.026 8.8 0.30 






(97.9) -2.1 -0.001 -4.1 0.16 









(95.7) 65.1 0.105 45.4 <0.001 
(n) (52) (50)  (49) (47)     
Diff- difference, NIE- Net intervention effect, HTN – hypertension, MgSO4- magnesium sulphate 
Perception and Practice of Anti-Hypertensive Drug Use 
PHC providers’ knowledge of specific drug use, namely alpha methyldopa, to control BP during pregnancy 
significantly improved in both groups (Table 5). About one third of providers in the intervention group 
prescribed alpha methyldopa at endline, while one sixth in the comparison group did the same (Table 7, 
following page). Differences in prescribing alpha methyldopa, between baseline and endline in both groups, 




TABLE 7  PHC provider perceptions and prescribing practices for anti-hypertensive drugs 
 
Comparison, n (%) Intervention, n (%)    






safety for HDP 18 (34.6) 50 (100.0) 65.4 14 (28.6) 47 (100.0) 71.4 -0.301 6.0 0.53 
What specific drugs are used (could be prescribed) to control BP during pregnancy? 
Alpha Methyldopa 47 (90.4) 47 (94.0) 4.4 35 (71.4) 44 (93.6) 22.2 -0.098 18.6 0.04 
Labetalol 3 (5.8) 0 (0.0) -5.8 9 (18.4) 1 (2.1) -16.3 0.074 -10.5 0.13 
Nifedipine  2 (3.8) 3 (6.0) 2.8 4 (8.2) 2 (4.3) -3.9 0.013 -6.1 0.36 
Hydralazine  0 (0.0) 0 (0.0) 0.0 1 (2.0) 0 (0.0) -2.0 0.010 -2.0 0.31 
Prescribed anti-hypertensive drug during pregnancy 
Alpha 
Methyldopa 6 (11.5) 8 (16.0) 4.5 9 (18.4) 13 (27.7) 9.3 0.091 4.8 0.66 
Labetalol 0 (0.0) 2 (4.0) 4.0 3 (6.1) 3 (6.4) 0.3 0.042 -3.7 0.51 
Nifedipine  2 (3.8) 2 (4.0) 0.2 4 (8.2) 0 (0.0) -8.2 0.002 -8.3 0.14 
(n) (52) (50)  (49) (47)     
Diff- difference, NIE- Net intervention effect, HTN – hypertension, MgSO4- magnesium sulphate 
Provider Practice with Antenatal Care Clients 
Client-provider interactions (CPI) with ANC clients were observed in all facilities, to assess HDP 
management practices (Table 8). Significant positive changes were observed from baseline to endline 
among intervention facility providers in hypertension and high BP history-taking (p<0.05) as well as 
checking for albumin in urine (p<0.001), compared to comparison facilities, yet some provider practices in 
comparison facilities were significantly better at endline than in intervention facilities. There was a 40 
percent increase among comparison providers who advised ANC patients about severe headaches from 
baseline to endline, compared to a 10 percent increase among intervention providers (p<0.05) (Table 8).  
As comparison and intervention areas for this anti-hypertensive study were selected within Ending 
Eclampsia project core intervention areas, some positive changes in provider HDP care practices were 
observed in both comparison and intervention areas from baseline to endline. 
TABLE 8 Effects of intervention on providers practices in managing HDP through CPI 




value Baseline Endline Diff Baseline Endline Diff 






(54.3) 43.8 0.098 25.8 0.03 






(82.9) 82.9 -0.028 -0.2 0.98 






(8.6) 8.6 -0.002 1.0 0.98 






(7.1) 7.1 -0.010 -1.3 0.81 






(100.0) 29.8 -0.045 12.5 0.12 






(84.3) 84.3 0.375 73.1 <0.001 






(42.9) 9.6 -0.158 -30.7 0.02 






(44.3) 33.8 -0.094 -24.2 0.03 




Diagnosis and Management 
Providers’ diagnoses of patients upon their enrollment, their service provision, and management of HDP 
were assessed. Table 9 demonstrates that HDP classifications among patients were similar in both facility 
groups. Only moderate to severe hypertensive patients were enrolled in the study for management and 
follow up. Among women with moderate to severe hypertension who required anti-hypertensive drugs upon 
diagnosis, all women in the intervention group received alpha methyldopa, while none in the comparison 
group did (p<0.001). Moreover, 45 percent of women with severe PE in the intervention group received a 
loading dose of MgSO4 upon diagnosis, compared to 38 percent in the comparison group (p<0.001; Table 
9).  
Nearly all (97%) women with moderate to severe hypertension in all facilities were referred to other facilities 
for further management. Among referred patients, 62 percent of those from intervention facilities and 51 
percent from comparison facilities presented for further treatment at referral facilities, which indicates that 
a substantial percentage of women did not complete the referral process and required further medical 
attention. 
TABLE 9  Hypertension diagnosis at enrollment, services received, and management in pregnancy 






Diagnosis at enrollment     
Chronic HDP 11 (7.2) 3 (4.8) 8 (8.9) 
0.75 Gestational HTN 66 (43.4) 29 (46.0) 37 (41.6) PE 26 (17.1) 10 (15.8) 16 (17.9) 
Severe PE 49 (32.2) 21 (33.3) 28 (31.5) 
Did service providers provide medicine 145 (95.4) 56 (88.9) 89 (100.0) <0.001b 
Service providers supplied medicine from facilities*     
Alpha Methyldopa 89 (58.6) 0 (0.0) 89 (100.0) <0.001b 
Calcium 67 (44.1) 42 (66.7) 25 (28.1) <0.001 
Iron 81 (53.3) 43 (68.3) 38 (42.7) 0.002 
Injection MgS04 loading dose 64 (42.1) 24 (38.1) 40 (44.9) 0.40 
Provider informed how to take medicine*     
Need to take every day until delivery 62 (40.8) 22 (34.9) 40 (44.9) 0.22 
Purchase from pharmacy if cannot re-fill at facility 5 (3.3) 3 (4.8) 2 (2.3) 0.39b 
Return if any side effects 16 (10.5) 3 (4.8) 13 (14.6) 0.06b 
Take single dose and go to higher facility 91 (59.8) 6 (9.5) 85 (95.5) <0.001 
Respondent had both MgS04 loading dose and alpha 
methyldopa 46 (30.3) 6 (9.5) 40 (44.9) <0.001 
Did provider give referral slip and instruct to go to 
higher facility 147 (96.7) 61 (96.8) 86 (96.6) 0.57
b 
(n) (152) (63) (89)  
Did respondent go to referral facility     
Yes 84 (57.1) 31 (50.8) 53 (61.6) 0.19 No 63 (42.9) 30 (49.2) 33 (38.4) 
(n) (147) (61) (86)  





Pregnancy Outcomes for Women with Hypertensive Disorders in Pregnancy 
Women in both groups were followed throughout their pregnancies, to assess their pregnancy outcomes. 
Between the two groups there was no significant difference in gestational age, mode or place of delivery, 
assistance during delivery, and maternal outcomes. About four fifths of all women with HDP delivered at 
36 weeks or later, while a small proportion, in all groups, delivered before 33 weeks (Table 10). No maternal 
deaths occurred in either group among those who sought services from PHC facilities.    
There were significant differences in infants’ outcomes (p<0.001). More infants died in the comparison 
group (14%; n=9) than in the intervention group (3%; n=3). Further analysis shows that hypertensive women 
who received alpha methyldopa were 1.36 times more likely to deliver a live infant than to women who did 
not receive alpha methyldopa during pregnancy (AOR:1.36, 95% CI:0.30-5.43). 
TABLE 10  Pregnancy outcomes among hypertensive women 
Indicator Total, n (%) Comparison, n (%) Intervention, n (%) p-valuea 
Gestational age at delivery (week)     
<33 4 (2.6) 3 (4.8) 1 (1.1) 
0.49b 33-36  24 (15.8) 10 (15.9) 14 (15.7) 
>36 124 (81.6) 50 (79.3) 74 (83.2) 
Mode of delivery     
C-section 74 (48.6) 29 (46.0) 45 (50.6) 0.58 Normal delivery 78 (51.4) 34 (54.0) 44 (49.4) 
Place of delivery     
Home 30 (19.7) 9 (14.3) 21 (23.6) 
0.27 Government hospital 63 (41.5) 30 (47.6) 33 (37.1) 
Private hospital 59 (38.8) 24 (38.1) 35 (39.3) 
Who assisted in delivery*     
Doctors 88 (57.9) 31 (49.2) 57 (64.0) 0.07 
Nurses 106 (69.7) 45 (71.4) 61 (68.5) 0.70 
FWV 15 (9.9) 7 (11.1) 8 (8.9) 0.58 
Trained TBA 6 (3.9) 2 (3.2) 4 (4.5) 0.68b 
Untrained TBA 19 (12.5) 6 (9.5) 13 (14.6) 0.35 
Relatives/Neighbor 30 (19.7) 14 (22.2) 16 (17.9) 0.41 
Maternal outcome     
Alive 152 (100.0) 63 (100.0) 89 (100.0) - 
Newborn outcome     
Alive 130 (85.5) 54 (85.7) 76 (85.4) 
0.001b Not alive 12 (7.9) 9 (14.3) 3 (3.4) 
Sick 10 (6.6) 0 (0.0) 10 (10.2) 
(n) (152) (63) (89)  
Women gestational age (week) at delivery (newborn was not alive)  
<33 1(8.3) 1(11.1) 0(0.0) 
0.80b 33-36  3(25.0) 2(22.2) 1(33.3) 
>36 8(66.7) 6(66.7) 2(66.7) 
(n) (12) (9) (3)  
Women gestational age (week) at delivery (newborn was sick)  
<33 0(0.0) 0(0.0) 0(0.0) 
- 33-36  2(20.0) 0(0.0) 2(20.0) 
>36 8(80.0) 0(0.0) 8(80.0) 
(n) (10) (0) (10)  





Facility Readiness for Services to Hypertensive Pregnant Women 
The pre-intervention assessment revealed similarities with all facilities’ equipment availability, with 
shortages in functional sphygmomanometers and stethoscopes, as well as unexpired dipsticks for urine 
albumin tests (Table 11). There were virtually no commodities (alpha methyldopa and MgSO4 injections) at 
any facilities at baseline. At endline, equipment and commodities were available and functional in all 
facilities—except alpha methyldopa, which was only available in intervention facilities. 
TABLE 11 Effects of intervention on facility readiness for managing HDP 
 





value Baseline Endline Diff Baseline Endline Diff 
Diagnosis Equipment          
Presence of functional 
sphygmomanometer 17 (73.9) 23 (100.0) 26.1 24 (77.4) 31 (100.0) 22.6 0.017 -3.5 0.77 
Presence of functional 
stethoscope 20 (87.0) 23 (100.0) 13.0 24 (77.4) 31 (100.0) 22.6 -0.047 9.6 0.38 
Presence of unexpired 
dipstick  2 (8.7) 23 (100.0) 91.3 2 (6.5) 31 (100.0) 93.5 0.010 2.2 0.76 
Medicines          
Presence of alpha 
methyldopa 0 (0.0) 1 (4.3) 4.3 0 (0.0) 31 (100.0) 100.0 0.478 95.7 <0.001 
Presence of MgSO4 
loading dose (10gm) 1 (4.2) 23 (100.0) 95.8 0 (0.0) 31 (100.0) 100.0 -0.021 4.3 0.25 
(n) (23) (23)  (31) (31)     
Antenatal Care Utilization and Hypertension in Pregnancy Detection  
Service statistics from all study facilities were collected each month. Baseline data of ANC service utilization 
were collated for three months prior to the intervention, and then throughout the 15 months of the 
intervention. A high proportion of women, in all facilities, and all time periods, had BP measured. In 
intervention facilities, 10 percent more women had urine tests for albumin, per national standards, during 
the intervention than at baseline, which was significantly greater than the change in comparison facilities. 
Service providers cited lack of toilet facilities at PHC facilities and satellite clinics, provider negligence in 
choosing to whom to offer services, and client refusals to explain lack of urine testing.  
Significantly more women were detected with elevated BP in the intervention group, when comparing 
baseline and intervention periods (Table 12 and figures 3 to 7, Appendix D; monthly detection of moderate 
to severe hypertension in ANC visits at all facilities is provided in Figure 8 in Appendix D). 
TABLE 12  Service statistics for ANC utilization and proportion of HDPs detected, all data periods   
Indicator 





Baseline  Study  % Change Baseline  Study  
% 
Change p value 
# of ANC visits, per month 
(new and repeat contacts) 2,580 2,379 -8.5 2,676 2,679 0.1 8.6 -1.88 0.02 
#/% of women in ANC 








(95.9%) -1.5 3.1 -1.80 0.03 
#/% of women in ANC 








(67.4%) 13.9 24.9 2.79 <0.001 
#/% of women in ANC 













Researchers conducted in-depth interviews (IDIs) at endline with postpartum women who survived PE/E, 
at both intervention (n=13) and comparison sites (n=7), to understand their perceptions and experiences 
of their own hypertension or PE/E, and the services they received. 
Perceptions of Hypertension in Pregnancy, Pre-Eclampsia or Eclampsia,  
and Their Care  
Women in both study areas have similar ANC views and health-seeking behaviors, mostly visiting a health 
facility for normal check ups at later stages of pregnancy. A few women visited a facility for symptoms such 
as headache, dizziness, blurred vision, abdominal pain, or fever. Some women had a severe headache or 
blurred vision but did not visit a health facility because they thought they were normal pregnancy 
phenomena and that the symptoms would dissipate with rest. Many women do, however, correlate 
headaches and dizziness with high BP.  
More than half of interviewed women realized their HDP only at the end of the pregnancy, when informed 
by a service provider, not recognizing HDP’s onset. About one fourth of patients in both groups understood 
that hypertension could develop during pregnancy but knew no signs nor symptoms. Women were not 
aware of PE/E specifically but knew of potential pregnancy complications such as convulsions and bleeding.   
“I went to the nearby health facility at seventh month of my pregnancy. It was my second 
pregnancy. I had no problems in my first pregnancy. You know, there are always some problems 
when you got pregnant, this is normal thing. You want to have a child…no problem, it may not 
happen. Apa [service provider] told me that my pressure is about 160, which is too high. I had 
severe headache before, but I never come to this health facility.” 
                                                          Survivor, 21 years old, multigravida, Intervention Area 
“I have taken antenatal care services once at ninth month of my pregnancy. I went to nearby 
Jaforgonj Family Welfare Center [PHC facility], Pervin Apa [FWV] measured my blood pressure and 
said my pressure is high. She gave me a medicine to take, administered injections in my buttock. 
Then, she referred me to the Cumilla Medical College and Hospital [tertiary referral hospital].” 
                                                                    Survivor, 28 years old, multigravida, Intervention Area 
“At the last stage of my pregnancy, when I went to Balla Family Welfare Center, I got to know that 
my blood pressure is high. I don’t know how much…I had no serious problems during the pregnancy 
period but always felt dizzy. Apa [service provider] told me my pressure is too high and I need some 
injection…visit…a physician or higher facility. She gave me two injections. There were four injection 
ampules. I don’t know the name of injection. Then she referred me to District Hospital, Tangail.” 
                               Survivor, 22 years old, primigravida, Comparison Area 
Women’s Responses to Referrals 
Most pregnant women in both groups visited referral facilities as a result of provider referral. A few referred 
women did not complete their referral processes and stayed home, in the belief that they felt well. Women 
who did not complete their referrals stated that they would visit a referral facility only if symptoms worsened. 
Some women believe in local, traditional medicines and visit health care facilities only for a severe problem.  
“In the eighth month of my pregnancy, the doctor at Family Welfare Center told me that my blood 
pressure is high. She also…gave medicines for high pressure. I do not know the name of medicine. 
She also administered injection in my waists. She told me to go Burichong Upazila Health Center 
for better management…I didn’t go anywhere; it is too far. I stayed at home. I had labor pain at 




“From Elenga UH&FWC they referred me to Tangail District Hospital. My parent took me there 
immediately. I had high blood pressure. They prescribed me medication for high blood pressure. 
When I started feeling better, they told me that my physical condition is alright. They told my father 
to take me home. Then I came back.”            Survivor, 28 years old, primigravida, Comparison Area 
“Initially, I didn’t visit any doctor. I took homeo[pathic]  medicine for having normal delivery, but 
later went to Shalla Family Welfare Center, where I got to know my pressure is high, and they 
referred me after primary treatment. I was admitted at Tangail District Hospital and had ‘caeser’ 
[cesarean section] there.”                               Survivor, 22 years old, primigravida, Comparison Area 
Women’s Perceptions of Service Provider Behaviors and Care 
Most women, in both study areas, reported high satisfaction of care and that their providers exhibited 
respectful attitudes towards them. Women stated that they receive adequate services from government 
PHC and referral facilities. A few women did mention that they visited a private clinic instead of a public 
referral facility because they believe doctors are not always available at government facilities. Women 
stated that service providers did not perform urine tests when they found high BP─they just refer.  
“I had severe labor pain at night but did not deliver in the whole morning, even. Then, I went to 
Sadar Hospital [public] on the day at three p.m. Doctor was unavailable there, so they said they 
can’t do delivery without doctor and asked me to take Mirjapur Hospital [private medical college]. 
My family thought it is too far from here and…can’t take me there during this critical time. So, they 
searched for a clinic nearer to us and we went to doctor’s [private] clinic and had cesarean section 
there.”                                                               Survivor, 22 years old, primigravida, Comparison Area 
“Service providers from Family Welfare Center were good. When I went there, no one was in the 
Center, but while they were informed about a patient and within half an hour, they attended me. 
They checked my pressure several times, with some intervals, and then she referred me to District 
Hospital; they told me that my pressure is high and need injection before going to District Hospital. 
After administering injection, I went to a clinic and had cesarean delivery there. Nurses of the clinic 
were very good, even they came to my home after delivery for follow up.” 
                                                                                Survivor, 22 years old, primigravida, Control Area 
“The Family Welfare Visitor was modest and helpful. She prescribed medicines, explained me 
about the problems may I have. She told me about the regularity of taking [blood] pressure drug.” 
                                            Survivor, 19 years old, multigravida, Intervention Area  
 “The services of FWC (PHC facility) was very good. I have not spent any extra money.” 
Survivor, 21 years old, multigravida, Intervention Area 
Women’s Perceptions of Anti-Hypertensives and Provider Counseling 
Women in both groups had minimum awareness of anti-hypertensive drugs. They mostly depend upon 
service provider recommendations. Interviewed women did not know the name of alpha methyldopa, or its 
use as an anti-hypertensive drug, particularly women in the intervention group. Women explained that 
providers offer minimum information when making recommendations to clients. Women said that providers 
also did not communicate their urine test results or BP measurements to them.  
“I have taken ANC services once at ninth month of my pregnancy. I went to nearby Jaforgonj Family 
Welfare Center—Family Welfare Visitor measured my pressure and said my pressure is high. She 
gave a medicine to take, administered injections in my buttocks. Then, she referred me to the 
Cumilla Medical College and Hospital. She didn’t tell much, just said ‘don’t wait, go quickly.’”                                                        





Views of Policy-Makers, Program Managers and Other Stakeholders 
Researchers conducted IDIs at endline with eight policy-makers and other stakeholders, as well as 10 
program managers, in both study areas, on their views and opinions of anti-hypertensive drugs.  
Anti-Hypertensive Drug Policy 
Most program managers, from both groups, stated that the government should allow PHC providers to 
provide anti-hypertensive drugs because it is a necessary part of the course of treatment for PE/E that is 
missing. They also mentioned delays in their patients reaching referral facilities after their referrals. Some 
women do not complete their referrals and return home, remaining untreated for high BP unless they are 
provided MgSO4 prior to referral. Most program managers expressed the need for changing the anti-
hypertensive drug policy, although a few believe PHC providers need more training and supervision, with 
some restrictions. A few also mentioned allowing other anti-hypertensive drugs, not only alpha methyldopa.  
“Yes, they should be allowed because huge number of pregnant mothers go to local health care 
facilities rather than the higher health care facilities to receive antenatal care service. So, if the 
PHC service providers can identify hypertension, pre-eclampsia, eclampsia and provide them with 
the possible treatment at the root level before referring to higher facility, it would reduce the 
damage that might have due to treatment delay from primary health care to referral center and 
mother and child morbidity and mortality will reduce to a great extent.” 
                                                               Sub-District Program Manager, Intervention area 
“We are procuring magnesium sulphate for the primary health care facilities, and we have already 
included magnesium sulphate in our operational plan 2017 to 2022. Regarding anti-hypertensive, 
we are waiting for your study results. After getting your study results, we will go further.” 
     Central Policy-Maker and Implementer, DGFP 
“I think the policy needs to be changed, we can approve the primary health care providers for 
prescribing a specific drug, specific dose and for a specific time duration.”    
District Program Manager, Intervention Area 
“As I have mentioned before, after ensuring their skills of measuring blood pressure, identifying 
pre-eclampsia or eclampsia and prescribing drug they can be allowed for this task. Mentorship is 
also needed to verify if works are being done accordingly, if yes, they are found efficient then 
primary health care providers would be allowed to prescribe anti-hypertensive drug.”  
                                                                   Sub-District Program Manager, Comparison Area 
“If BMRC gives permission, I think it would be better to administer labetalol instead of methyl dopa, 
because labetalol reduces the pressure quickly and methyl dopa takes some time…However, they 
need training to understand at which condition they will provide and to which amount. Sometimes 
even the doctors go on giving two, three, four doses if the pressure doesn’t come down. Alpha 
methyl dopa can cause fluid retention and in that case anti-hypertensive doesn’t work. Even our 
doctors can’t administer it properly—I’m speaking very frankly. Hence, when we are giving it to the 
Family Welfare Visitor, SACMO, and nurse/midwives, we need to give them a dosage limit which 
they shouldn’t cross. In that case, there won’t be a problem.”                             Former OGSB Official 
“There’s a procurement policy of the government. Injection magnesium sulphate procurement 
policy has been adopted. This drug we have listed in our operational plan. We’ve already 
recommended its use though we are waiting for your results. About anti-hypertensive drugs, we 
are thinking. National Technical Committee permitted to do research about Sardopa [alpha 
methyldopa] using by the primary health care provider and Population Council is conducting it. We 





Opinions of Task Sharing with Primary Health Care Providers 
All interviewed program managers stated that this intervention could have significant impacts in reducing 
maternal deaths. Community members first visit PHC facilities for services, and if PHC providers are 
equipped with appropriate knowledge and skills recommended for anti-hypertensive drug provision, and 
then refer women to higher levels of care, deaths due to PE/E can be reduced. Program managers 
emphasized the delays in patients reaching referral facilities as well as PHC providers’ roles in identifying 
and referring patients in a timely manner. Most Ob/Gyn professionals interviewed are in favor of task 
sharing, while government policy-makers would like to wait for study results.  
The Directorate General of Health Services (DGHS) supplies anti-hypertensive drugs to secondary and 
tertiary facilities, but it is not clear whether PHC providers such as nurses and midwives are allowed to 
prescribe them.  
“Currently, we don’t have anti-hypertensive at all facilities, we have to purchase it. Community-
based Health Care gives us some medicines, I don’t know whether they’re supplying it. But we only 
have magnesium sulphate. I have it in my mind that I’d add it during revision.”                                               
 Policy-Maker and Implementer, DGHS  
“Government needs to supply where they are supposed to supply. Mainly, the government should 
step forward. Why can’t they? The drug is unbelievably cheap, there’s no reason not to afford it. 
So, if we want to attain our Sustainable Development Goal targets, our first target would have to 
be point out these things. Now we’re wanting to increase the number of institution deliveries, but 
for that we need to make the institutions right in the first place. If we don’t get doctors there, we 
can train the FMVs and SACMOs to give certain injections and medications to save the mothers. 
Even this will be a lot. Some works are being done at the MCWC level, but at the union level they 
only refer. But at some places in the community level good deliveries are being done. But they 
need to be trained up. We need to train them to check the blood pressure, weight, anemia since 
the early pregnancy. We need to target these small things. If we can teach them to give anti-
hypertensive drug, calcium, check the urine albumin, creatinine level, then we can make much 
progress.”                                                                                                Former OGSB Official, Bangladesh 
“Obviously, it would help, because pregnant women go to the Upazila Health Center or higher 
health care centers much later. I think if there is antenatal care, postnatal care follow up center 
nearby, then the mothers will be able to go there primarily. I think most of them go to primary 
health care centers, as it’s not possible for many to go to higher health care centers due to 
transport, communication system, and other reasons. It’s also difficult to transfer pregnant 
mothers easily, so if the anti-hypertensive drug could be prescribed at the nearby community level, 
then the mothers could go there easily, though the patient should be referred to higher facility 
along with this.”                                                                              Program Manager, Intervention Area 
Program managers in comparison areas are also in favor of training PHC providers to prescribe anti-
hypertensive drugs. These program managers believe that if PHC providers can be trained on anti-
hypertensive use, it will be more efficacious, as they now only identify and refer, although they are allowed 
to administer an MgSO4 injection.  
“Yes, I did participate in the training on anti-hypertensive drug. Two doctors came as trainers. They 
explained everything beautifully, with hands on training. And, after the training, we are seeing that 
those who have received the training can identify hypertension, eclampsia, and pre-eclampsia. 
They are doing follow up and referring the patients. They are continuing these activities. I think, 
with training they can prescribe anti-hypertensive drug to the pregnant women.”                                               




“When a patient comes to the sub-district level, there may not be a doctor. In that case, as the 
primary health care providers are trained, they can give one alpha methyldopa and refer, it 
wouldn’t harm the patient.”                                                                               Deputy Program Manager 
“This intervention is very appropriate, because if our grassroot level isn’t conscious, if patients are 
not referred from there, then patients will only come to us at the very end. So, if we want to prevent, 
we have to start from the beginning. So, people who are working at the grassroot, they have 
received special training. And they are medical professionals, they are not lay people. So, they 
could grasp the training very easily, and they could understand the problem. And, as they face the 
problem first, they could understand which way is better. They’ve earned our faith because of our 
well training. Later, when I visited, I saw them working. So, I think it would be good if they can 
prescribe anti-hypertensive drug, magnesium sulphate, and then refer to higher level. And if 
patients aren’t referred from grassroot level, then prevention is never possible, we will get the 
patient [too] late to intervene.”                                                                                Former OGSB Official 
Opinions on Scaling up the Intervention 
Policy-makers, stakeholders, and program managers assert that reductions in maternal deaths due to PE/E 
require implementation of multiple initiatives. All health system informants suggested that MgSO4 and anti-
hypertensive drug interventions should be scaled up in other parts of the country, as PE/E is a major cause 
of preventable maternal deaths in Bangladesh.  
“Obviously. If this program is expanded to the entire country by government, then huge number of 
pre-eclampsia, eclampsia patients will be identified, and the primary health care providers can 
provide primary care and refer the severe patients to higher facility. This will lower the mother and 
child morbidity and mortality rate.”                         Sub-District Program Manager, Intervention Area 
Supply and Procurement of Anti-Hypertensive Drugs 
The Directorate General of FP does not supply alpha methyldopa to facilities, but DGHS has been supplying 
it to UHCs and DHs. According to stakeholders and program managers, the government should ensure 
availability of this drug in every health facility.  
“Locally, we local authorities cannot purchase anti-hypertensive drugs. Government should make 






This implementation science, within the greater Ending Eclampsia project, tested the feasibility of training 
PHC providers (FWVs, SACMOs, nurses) to detect HDPs, manage moderate to severe HDP with a single 
500mg dose of alpha methyldopa, and administer MgSO4 in cases of severe PE/E, and refer patients for 
continuing care. The results of this study may be affected by the Ending Eclampsia PHC PE/E core 
intervention that was implemented previously in this study’s intervention and comparison areas. PHC 
providers in comparison sites had already been trained to detect of high BP and administer MgSO4, which 
may have influenced some of the positive trends in comparison facilities. 
Despite demands on the public health system to meet new and future challenges, skill deficits within the 
health workforce are apparent (DeCorby et al 2018, Gebbie et al 2005). WHO suggests task sharing with 
lower level service providers when a workforce is insufficient (WHO 2008, 2012, 2017). This study 
demonstrates the potential of PHC provider task sharing for anti-hypertensive drug prescription. PHC 
providers at intervention facilities were able to correctly measure BP, classify it, provide a single dose of 
alpha methyldopa, and refer pregnant women in a timely manner, after capacity-building activities provided 
by the Ending Eclampsia project.  
In this study improvements in anti-hypertensive drug knowledge were similar for all sites, suggesting the 
effects of the core Ending Eclampsia PHC PE/E intervention. Most providers at endline could classify 
hypertension as mild, moderate, and severe. Providers’ knowledge of when to initiate anti-hypertensive 
drugs significantly improved in the intervention group, compared to the comparison group, although some 
improvements were also evident in the comparison group.  
A recent study linking DHS and facility readiness in sub-Saharan Africa showed particularly poor abilities 
for managing HDP in pregnancy that indicate that BP measurement alone may not be adequate for quality 
care (Kanyangarara et al 2017). Results from this study suggest that concomitant training on PE/E and 
anti-hypertensive drugs, such as administering MgSO4 to severe PE/E patients, is much better than PE/E 
training by itself. Simple interventions during pregnancy can have considerable impacts on important 
mortality outcomes (Hodgins et al 2016). An additional service component such as anti-hypertensive drug 
prescription can be incorporated within current service delivery models (Mammaro et al 2009, Hodgins et 
al 2018). Facility readiness must be confirmed in advance by ensuring availability of intramuscular 
injections of MgSO4, dipsticks for urine tests, BP machines, and stethoscopes (RCOG 2010).  
This study’s findings show almost universal BP measurement, but no significant increase in urine analysis 
for albumin. Provider practices for BP measurement and urine analysis, for all clients, must also be 
improved. A nationally representative study in Afghanistan showed similar findings, with not all women 
having BP and proteinuria checked when needed (Ansari et al 2019). A challenge for testing urine for 
albumin is a lack of toilets at facilities or their satellite clinics.  
Challenges identified in this study that must be addressed include providers’ determinations of whom to 
offer testing to, as well as patients’ refusals. Provider motivation and monitoring are important components 
as well (WHO 2011). Not every provider detected, or received for care, a pregnant woman with HDP who 
required a MgSO4 injection, or other hypertensive treatment. All patients with moderate to severe 
hypertension at intervention facilities were provided alpha methyldopa; only 28 percent of intervention site 
providers received or detected moderate to severe hypertensive patients.  
No maternal deaths occurred in any study PHC facility, however, a greater number of infants died in 
comparison referral facilities than in intervention referral facilities. Although maternal and perinatal 




intervention and comparison PHC facilities (89 and 63 women, respectively) were too small for definite 
conclusions—yet the impacts of this intervention on PHC providers shows potential and could be useful in 
other parts of the country, as demonstrated in other countries (DeCorby et al 2018, Okoli et al 2015). 
Pregnant women’s lack of adherence to referral processes and late ANC attendance are major challenges 
revealed by this study. Qualitative findings from survivor interviews suggest that many women do not seek 
early ANC unless they experience problems, and some women did not experience prodromal signs or 
symptoms, which raises concerns about how women and families can detect early onset hypertension. This 
is an issue that needs further exploration (Carter et al 2017). Similarly, many women do not visit referral 
facilities if they believe they feel better, due to medication from PHC providers or rest, or instead believe 
that referral facility providers are likely unavailable.  
Poor communication skills, from providers to their patients, and inadequate information provided to clients 
and their families about the severity of patient conditions or test results, very likely also play a role in 
patients’ non-adherence to the referral process. Only two fifths of patients observed during CPIs were 
cautioned that severe headache and blurred vision should be considered serious problems requiring urgent 
medical attention. If women and their families do not understand the seriousness of their problems and 
their potential consequences, they may be less likely to seek care with urgency.  
This study includes a few limitations, including non-independence of the samples. Paired sample analysis 
was impossible because of frequent PHC provider transfers between facilities, and new postings. DMOs 
did, however, mentor or train newly posted PHC providers, to ensure their competency for service.  
This study was encompassed by a larger Ending Eclampsia study that trained providers on MgSO4 and 
PE/E, which may have affected provider knowledge and practices. The objectives of both studies are 
similar, but only this study prescribed anti-hypertensive drugs. Researchers also observed CPIs to assess 
quality of care, which introduced the potential of a Hawthorne effect.  
To make these study findings robust, different data sources have been utilized, and findings have been 
compared. Nevertheless, this study demonstrates interesting results for policy-makers to consider for task 






Conclusions and Recommendations 
PHC providers (FWVs, SACMOs, nurses) should be allowed to prescribe anti-hypertensive drugs and 
refer patients to higher level facilities when needed. PHC providers are capable of correctly measuring BP, 
classifying it, prescribing single doses of alpha methyldopa, and referring patients other facilities for further 
management, in a timely manner. Because the health care system lacks the capacity to completely regulate 
PHC providers, they prescribe anti-hypertensive drugs for women with HDP, even though they are not 
permitted to do so—and mostly prescribe drugs that are contraindicated. This situation demands that PHC 
providers are provided with appropriate and accurate anti-hypertensive drug knowledge, and equipped with 
requisite skills, for safe provision of correct anti-hypertensive drugs and referrals for patients in appropriate 
time. 
PHC providers should be trained for three days—on hypertension, PE/E, MgSO4 and anti-
hypertensive drugs—as well as participating in a one day refresher workshop, after three months.  
Many women are not completing their courses of referral. Further research of these women is 
recommended, to identify why they do not complete the referral process, what are the barriers to 
their completion of the referral process are, and ways to support their completion of the process.   
To build upon the findings of this study, which examined the efficacy of a single dose of alpha methyldopa 
and referral, a life course study of the pregnancy period with anti-hypertensive drugs provided by 
PHC providers is recommended to assess PHC providers’ abilities in identifying drug non-responsiveness, 
emerging danger signs and symptoms, appropriate times for hospitalization or physician intervention, in 
addition to assessing whether task sharing is correct and adequate. 
Task sharing efforts, including anti-hypertensive drugs, particularly alpha methyldopa, that were 
part of this PHC PE/E implementation, are recommended for other parts of the country, to reduce 
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Appendix A  
Flow chart for diagnosis and management of HDPs 
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HTN     
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PE* Severe HTN(Chronic HTN or PIH) SPEPE* 
• No HTN drug
• Return in one week
• Regular monthly 
Checkup
• Inform the danger 
signs/symptoms of 
PE/E
• Dispense and prescribe HTN drug
• Regular ANC Checkup
• Inform the danger signs/symptoms of PE/E
• Refer to CEmOC
• Dispense and 
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• Inject MgSO4 10 
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Alternate
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• Refer to CEmOC
• Dispense and 
prescribe HTN drug
• Inject MgSO4 10 gm 
IM ( Alternate 
buttock 5 gm)
• Regular monthly ANC 
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• Inform the danger 
signs/symptoms of 
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• Refer to 
CEmOC
*Dispense and prescribe antihypertensive before 37 weeks, HTN=Hypertension, 
PE/E=Preeclampsia/eclampsia, PIH- Pregnancy induced hypertension
Danger sign/Symptoms: Severe Headache, Blurring of vision, upper abdominal pain 
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cases
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Figure 3 ANC utilization in 31 intervention facilities
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Figure 4 Proportion of women with both BP measured and urine checked 
during ANC visit in 31 intervention facilties





































































Figure 5 ANC utilization in 23 comparison facilities
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Figure 6 Proportion of women with BP measured and urine checked 
during ANC visit in 23 comparison facilities




























































Figure 8. Proportion of women with both BP measured and urine checked during 



























































Figure 9 Monthly detection of moderate to severe hypertension in ANC visits at 
intervention and comparison facilities during intervention period
Intervention Comparision
